4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-23-043982
Chief Financial Officer sold 1,245 shares at $9.65 ($12,020)
- Chief Financial Officer acquired 4,886 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
van Houte Hans · Chief Financial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-07-30 | Exercise or conversion : show line 1 in the form | +2,886 | 81,816 | D | ||
| 2023-07-30 | Exercise or conversion : show line 2 in the form | +2,000 | 83,816 | D | ||
| 2023-07-31 | Sale : show line 3 in the form | −1,245 | $9.65 | $12,020 | 82,571 | D |
| Open-market sales · 1,245 sh · avg $9.65 · $12,020 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-07-30 | Exercise or conversion : show line 4 in the form Restricted Stock Units | −2,886 | 28,861 | D |
| 2023-07-30 | Exercise or conversion : show line 5 in the form Restricted Stock Units | −2,000 | 22,000 | D |
Loading xslF345X05/doc4.xml…